课题基金 / 基金详情

项目摘要

项目成果

DIVAKER CHOUBEY的其他基金

相似基金

相关文献

中文摘要
翻译
系统性红斑狼疮(SLE)是一种自身免疫性疾病。这种疾病的发病比例是男女之比。 10:1。虽然,基因多态性、女性性激素雌激素和干扰素信号等几个因素, 与狼疮疾病的发展过程中的性别偏见有关,分子机制仍然存在 有待澄清。因此,了解候选狼疮易感基因的因果作用非常重要。 其表达受上述因素的调控。我们下一步拟进行的研究的主要目标 资助期是:(I)了解性激素(雌激素和睾丸素)如何不同地调节 狼疮候选易感基因Ifi202(编码p202蛋白)在新西兰的表达 小鼠1号染色体上黑色(NZB)来源的Nba2区间;和(Ii)定义p202蛋白在性别中的作用 狼疮易感性的偏向。P202蛋白(~52-kDa)是一种可诱导的转录调节因子 如P53、E2F1、NF-κB、AP-1等。多种细胞类型中p202蛋白水平升高 抑制细胞周期进程,调节细胞存活。根据我们的初步观察和其他观察,我们 假设启动子基因多态和性激素导致人卵巢癌IFI202基因表达增加 某些易患狼疮的雌性小鼠品系。此外,我们假设B细胞中p202蛋白水平的增加 T细胞通过增加细胞凋亡的阈值而增加狼疮的易感性。P202蛋白 通过调节核因子-κB和c-jun/AP-1的转录活性,提高细胞凋亡的阈值。 目标1:确定女性性激素雌激素和男性性激素雄激素如何通过它们的受体 (雌激素受体-α和AR)分别调节B细胞和T细胞中IFI202的表达。目标 #2:研究B6Nba2同源免疫细胞中p202蛋白水平的增加 C57BL/6遗传背景)小鼠Nba2间隔期下调Fcgr2b基因表达 (编码抑制性Fc受体FcγRIIB)。目的#3:阐明其分子机制。 B6Nba2淋巴细胞(B细胞和T细胞)p202蛋白水平的增加对 核因子-κB和c-jun/AP-1的转录活性。意义:证明我们的假设具有重要意义 对理解狼疮发病机制中性别偏见的分子基础的启示。 重要的是,我们的研究结果有可能确定用于诊断和治疗的分子靶点。 狼疮的治疗干预。
英文摘要
Systemic lupus erythematosus (SLE) is an autoimmune disease. The disease develops at a female-to-male ratio of 10:1. Although, several factors, such as gene polymorphisms, female sex hormone estrogen, and interferonsignaling, are implicated in gender bias in the development of lupus disease, the molecular mechanisms remain to be elucidated. Therefore, it is important to understand the causal role of candidate lupus susceptibility genes whose expression is regulated by the above factors. The major objectives of our proposed studies in the next funding period are to: (i) understand how sex hormones (estrogen and testosterone) differentially regulate the expression of Ifi202, a candidate lupus susceptibility gene (encoding p202 protein) within the New Zealand Black (NZB)-derived Nba2 interval on murine chromosome 1; and (ii) define the role of the p202 protein in sex bias in lupus susceptibility. The p202 protein (~52-k Da) is an inducible modulator of transcriptional activities of factors, such as p53, E2F1, NF-κB, and AP-1. Increased levels of p202 protein in a variety of cell types inhibit cell cycle progression and modulate cell survival. Based on our preliminary and other observations, we hypothesize that promoter polymorphisms and sex hormones contribute to increased expression of Ifi202 in certain lupus-prone strains of female mice. Moreover, we postulate that increased levels of p202 protein in B and T cells contribute to lupus susceptibility by increasing the threshold for apoptosis. The p202 protein increases the threshold for apoptosis by modulating the transcriptional activities of NF-κB and c-Jun/AP-1. Aim #1: Determine how female sex hormone estrogen and male sex hormone androgen through their receptors (estrogen receptor-α and AR, respectively) differentially regulate the expression of Ifi202 in B and T cells. Aim #2: To investigate how increased levels of p202 protein in immune cells of B6.Nba2 congenic (congenic for the Nba2 interval on C57BL/6 genetic background) mice down-regulate the expression of the Fcgr2b gene (encoding the inhibitory Fc receptor FcγRIIB). Aim #3: To elucidate the molecular mechanisms by which increased levels of p202 protein in B6.Nba2 lymphocytes (B and T cells) differentially modulate the transcriptional activities of NF-κB and c-Jun/AP-1. Significance: Proving our hypotheses has important implications for the understanding of the molecular basis of sex bias in pathogenesis of lupus disease. Importantly, the results from our studies have the potential to identify the molecular targets for diagnosis and therapeutic interventions in lupus disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
AIM2 and IFI16 Innate Immune Sensors for Cytosolic DNA in Prostatic Diseases
AIM2 and IFI16 Innate Immune Sensors for Cytosolic DNA in Prostatic Diseases
AIM2 and IFI16 Innate Immune Sensors for Cytosolic DNA in Prostatic Diseases
AIM2 and IFI16 Innate Immune Sensors for Cytosolic DNA in Prostatic Diseases
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: